Health

Key Milestone: The first patient successfully dosed with the candidate drug SR419 for peripheral neuropathic pain

SHANGHAI, Sept. 21, 2020 /PRNewswire/ -- Shanghai SIMR Biotechnology Co., Ltd. (hereinafter referred to as "SIMR" or "Company") announced that, the clinical trial in patients with peripheral neuropathic pain has been initiated for the candidate drug SR419, and the first patient has been successfu...

2020-09-21 10:35 70

UN75 Dialogue - Family Mask and its #BackToSchool Initiative for Global Goals Week 2020

HONG KONG, Sept. 21, 2020 /PRNewswire/ -- To celebrate United Nations and its 75 th anniversary, Family Mask organized #KIDsforSDGs program which achieved great success and received feedbacks on global issues and role of the UN from the students. Family Mask collected all the feedbacks and will la...

2020-09-21 09:38 404

Viva Biotech and SYNthesis Enters a Strategic Acquisition Agreement, Accelerating the Development of Global Innovative Drug R & D Service Capabilities

SHANGHAI, Sept. 21, 2020 /PRNewswire/ -- Viva Biotech (Shanghai) Co., Ltd. (hereinafter referred to as "Viva Biotech" or "The Company") entered into the Share Purchase Agreement pursuant to which Viva Biotech agreed to acquire and the Vendors agreed to collectively sell 100% of the equity interes...

2020-09-21 09:25 371

Innovent and Lilly Release Biomarker Results of TYVYT® (Sintilimab Injection) in Combination with ALIMTA® (Pemetrexed) and Platinum Chemotherapy as First-Line Treatment for Nonsquamous Non-Small Cell Lung Cancer at ESMO Virtual Congress 2020

SAN FRANCISCO and SUZHOU, China, Sept. 21, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other majo...

2020-09-21 08:00 666

Innovent and Lilly Jointly Release Phase 3 Results of TYVYT® (Sintilimab Injection) in Combination with GEMZAR® (Gemcitabine) and Platinum Chemotherapy as First-Line Treatment for Squamous Non-Small Cell Lung Cancer at ESMO Virtual Congress 2020

SAN FRANCISCO and SUZHOU, China, Sept. 21, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other majo...

2020-09-21 08:00 824

WellsCare signs in-store contract with b8ta for IASO

SEOUL, South Korea, Sept. 20, 2020 /PRNewswire/ -- WellsCare, a member company of theBorn2Global Centre, recently signed a store contract with b8ta, a famous American flagship store that is dedicated to innovative products. WellsCare has been an active member of the Born2Global Centre since 2019....

2020-09-20 20:00 1151

Preparation products of Yiling Pharma approved by FDA for launch in the US market

SHIJIAZHUANG, China, Sept. 19, 2020 /PRNewswire/ -- Yiling Pharmaceutical Co., Ltd. announced on Friday that it had received the approvals of the Abbreviated New Drug Applications (ANDA) about Lisinopril Tablets and Acyclovir Capsules, from United States Food and Drug Administration (hereinafter ...

2020-09-19 19:14 1793

LUFTQI Launched a Crowdfunding Campaign for the LUFT Duo Filter-Free Air Purifier

TAOYUAN, Sept. 18, 2020 /PRNewswire/ -- Multiple fast-moving wildfires are continuing to burn across Califronia,Oregon and Washington, threatening people and homes. For essential worker commuters, including gig workers, this also means potential respiratory problems for those forced to drive unde...

2020-09-18 20:00 2999

BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine

Not intended for US-, Canada- and UK-based media DARMSTADT, Germany, and NEW YORK, Sept. 18, 2020 /PRNewswire/ -- Merck and Pfizer Inc. (NYSE: PFE) today announced the publication of detailed results from the Phase III JAVELIN Bladder 100 study online ahead of print inThe New England Journal of...

2020-09-18 15:00 6005

PolyU designs new dual-task exercise for stroke patients to effectively reduce the risk of falls and fall-related injuries

HONG KONG, Sept. 18, 2020 /PRNewswire/ -- Stroke is the fourth leading cause of death inHong Kong[1], hospitalising around 25,000 people each year[2]. Despite declines in stroke mortality over the past years, it remains one of the major causes of adult disability, greatly affecting the daily live...

2020-09-18 10:08 2009

Setting new standards for speed and compatibility: Medit launches new T-Series scanner models

SEOUL, South Korea, Sept. 18, 2020 /PRNewswire/ -- Medit announces the launch of three new T-Series laboratory scanner models; T710, T510, and T310. The new T-Series laboratory scanner lineup – the T710, T510, and T310 – is carefully designed...

2020-09-18 09:49 2010

Apis Partners leads US$15 million investment in Prenetics

* Investment will go into game-changing rapid COVID-19 test, highly accurate, results in 15-30 minutes, no lab required, low-cost. In discussions with Governments globally. * Enabling Travel Bubble: Prenetics, Cathay Pacific to launch pilot in October 2020 from HKG to LHR with The Commons Pro...

2020-09-18 08:00 2938

MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210/TJ210 in Patients with Advanced Cancer

PLANEGG/MUNICH, Germany and SHANGHAI, China, Sept. 17, 2020 /PRNewswire/ -- MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and I-Mab (Nasdaq: IMAB) today jointly announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug applic...

2020-09-18 04:05 7549

First patient in treatment in RhoVac's clinical phase IIb study in Sweden

STOCKHOLM, Sept. 17, 2020 /PRNewswire/ --  RhoVac AB ("RhoVac") announces today, onSeptember 17 2020, that the first patient in Sweden is enrolled in the company's clinical phase IIb study in prostate cancer, a study named RhoVac-002 ("BRaVac"). The first patient in Sweden is enrolled in the cli...

2020-09-17 23:51 2286

Dr. Steven Yu Joins ChemPartner as Vice President of Regulated Bioanalysis

SHANGHAI, Sept. 17, 2020 /PRNewswire/ -- Shanghai ChemPartner announced today the appointment ofSteven Yu, Ph.D. as Vice President of Regulated Bioanalysis at the company headquarters inShanghai, China. Dr. Yu has more than 15 years of experience in drug development and extensive expertise in...

2020-09-17 23:01 1262

Happy Buy Reached Cooperation With Hive-Box, Testing Water In Community E-Commerce

NANPING, China, Sept. 17, 2020 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovativeChina-based nutraceutical and dietary supplements producer, announced today that C'est La Vie Interactive Technology Co., Ltd ("CLV") , a subsidiary of Happy Buy, has signe...

2020-09-17 22:00 9712

Expanding Their Existing Strategic Collaboration, GenScript ProBio Licensed Global Rights to Develop and Commercialize a SMAB Bispecific Antibody Molecule to REMD Biotherapeutics Inc.

NANJING, China, Sept. 17, 2020 /PRNewswire/ -- On September 16th, 2020, GenScript ProBio and REMD Biotherapeutics Inc. (REMD) announced that REMD has licensed a bispecific antibody derived from the Single-domain antibody fused to Monoclonal Ab (SMAB) platform developed by GenScript ProBio. REMD i...

2020-09-17 22:00 1168

Nebulyft® Skincare Device Set to Transform the Anti-Aging Landscape

IRVINE, Calif., Sept. 17, 2020 /PRNewswire/ -- Rebeccatech LLC is proud to introduce the Nebulyft®, World's 1st MicroRF anti-aging device that's truly non-intrusive. nebulyft anti-aging device by Rebeccatech The Nebulyft® skincare device...

2020-09-17 21:19 963

Asia-Pacific's 5G Digital Factory Revenue Primed for a Post-COVID-19 Recovery Worth US$60 Billion in 2030

SINGAPORE, Sept. 17, 2020 /PRNewswire/ -- COVID-19 initially slowed mobile phone sales in theAsia Pacific and disrupted supply chains and demand for certain 5G-related end verticals. However, it also caused an increase in broadband traffic and 5G use cases such asSouth Korea using 5G to livestrea...

2020-09-17 20:30 2542

Viva Biotech's Portfolio Company Dogma Therapeutics Reached the Acquisition Agreement with AstraZeneca on Dogma's Oral PCSK9 Inhibitor Program

CAMBRIDGE, Mass., Sept. 17, 2020 /PRNewswire/ -- Dogma Therapeutics ("Dogma"), a Viva Biotech Portfolio Company, has reached an agreement for the acquisition of its oral PCSK9 program by AstraZeneca. Dogma will receive upfront as well as downstream payments linked to global regulatory and commerc...

2020-09-17 20:25 2331
12345 ... 902